The Therapeutic Potential of ADSC-Secreted LEFTY2 in Treating Alzheimer’s Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073382 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Wei Wuli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan. Hauptthemen laut MEDLINE: Alzheimer Disease, Mesenchymal Stem Cells, Left-Right Determination Factors, Adipose Tissue. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Gwo Xi Stem Cell Applied Technology Co., Ltd, Gwo Xi Stem Cell Applied Technology Co., Ltd..
Themen: Demenz
Abstract (Originalsprache)
Adipose-derived mesenchymal stem cells (ADSCs) have exhibited promising therapeutic potential in Alzheimer’s disease (AD), although the underlying mechanisms remain poorly understood. Previously established Alzheimer’s disease neuron models derived from Ts21-induced pluripotent stem cells (Ts21-iPSCs) have been shown to exhibit progressive amyloid beta accumulation during neuronal differentiation. In this study, we employed a Transwell co-culture system to investigate the interaction between neurons derived from Ts21-iPSCs and ADSCs. Our findings revealed that co-culture with ADSCs significantly enhanced the survival rate of AD neurons. Proteomics analysis identified significant upregulation of left–right determination factor 2 (LEFTY2) protein in the co-culture medium. Supplementation with 2 nM LEFTY2 markedly improved the survival and growth of AD neurons. Furthermore, LEFTY2 effectively downregulates the expression of apolipoprotein E4 and amyloid beta 1–42, along with attenuating phosphorylated tau231 levels in AD neurons. These results suggest the potential of LEFTY2 as a promising therapeutic candidate for Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.
- Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.
- Department of Life Science, National Dong Hwa University, Hualien 974301, Taiwan.
- Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 97004, Taiwan.
- Department of Pathology, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.
- Department of Neurology, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.
ORCID-Profile: Wei Wuli, Peng Yeong Woon, Cynthia Tjandra, Shinn-Zong Lin
Förderung
- National Science and Technology Council
- Gwo Xi Stem Cell Applied Technology Co., Ltd
- Gwo Xi Stem Cell Applied Technology Co., Ltd.
Zitieren
APA
Wuli, W., Yang, H. H., Chiou, T. W., Woon, P. Y., Xu, Y. X., Tjandra, C., Wijaya, I., Harn, H. J., & Lin, S. Z. (2025). The Therapeutic Potential of ADSC-Secreted LEFTY2 in Treating Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073382
Vancouver
Wuli W, Yang HH, Chiou TW, Woon PY, Xu YX, Tjandra C, et al. The Therapeutic Potential of ADSC-Secreted LEFTY2 in Treating Alzheimer’s Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073382
BibTeX
@article{Wuli2025,
author = {Wuli, Wei and Yang, Hsueh-Hui and Chiou, Tzyy-Wen and Woon, Peng Yeong and Xu, Yue-Xuan and Tjandra, Cynthia and Wijaya, Ivan and Harn, Horng-Jyh and Lin, Shinn-Zong},
title = {The Therapeutic Potential of ADSC-Secreted LEFTY2 in Treating Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073382}
}
EUVIMED